We’re sitting down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research, development, and cutting-edge technology within the industry. With a career dedicated to pushing the boundaries of innovation, Ivan offers a unique perspective on how science and tech intersect
Drug discovery has long been a daunting endeavor, with the staggering statistic that developing a single new drug can cost upwards of $1 billion and take over a decade to reach the market. Imagine a world where this timeline is slashed, costs are dramatically reduced, and even smaller research
Imagine a world where life-saving treatments for cancer, autoimmune diseases, and metabolic disorders no longer require hours of intravenous infusions in a clinical setting, allowing patients to administer their medications at home with a quick injection, reclaiming time and autonomy. This scenario
In the intricate world of biopharmaceuticals, where the journey from drug discovery to patient delivery is fraught with challenges, the roles of Clinical Operations (ClinOps) and Medical Affairs (MA) stand out as indispensable. ClinOps serves as the operational backbone, meticulously managing
In the fast-evolving landscape of obesity treatment, where pharmaceutical companies race to deliver groundbreaking solutions, Viking Therapeutics emerged with high hopes for their oral weight loss drug, VK2735. Touted as a convenient alternative to injectable therapies dominating the market, this
In a world where the intersection of technology and healthcare is becoming ever more critical, Recursion Pharmaceuticals emerges as a trailblazer with a mission to transform the landscape of drug discovery through artificial intelligence (AI). Listed on NASDAQ under the ticker RXRX, this innovative
